Co-administration of Evotaz and indinavir is not recommended. Reversible elevations in indirect (unconjugated) bilirubin related to inhibition of UDP-glucuronosyl transferase (UGT) have occurred in patients receiving atazanavir. Indinavir is also associated with indirect unconjugated hyperbilirubinemia due to inhibition of UGT. Combinations of Evotaz and indinavir have not been studied and co-administration of these medicinal products is not recommended.

Coadministration is contraindicated as both atazanavir and indinavir are associated with indirect (unconjugated) hyperbilirubinemia.

Atazanavir, as well as indinavir, is associated with indirect (unconjugated) hyperbilirubinemia due to inhibition of UDP-glucuronosyltransferase (UGT). Combinations of atazanavir with or without ritonavir and indinavir have not been studied and co-administration of these medicinal products is not recommended due to the risk of worsening of these adverse effects.

Both indinavir and atazanavir are associated with indirect (unconjugated) hyperbilirubinemia. Combinations of these drugs have not been studied and coadministration of indinavir and atazanavir is not recommended.